As a preclinical CRO specializing in oncology, Alfa Cytology provides polyclonal stable cell line construction services designed to meet the demand for rapid and cost-effective cell populations in your early-stage research. By applying drug selection to transfected cell populations, we generate stable mixed clone pools that enable you to rapidly assess gene expression and biological function, accelerating the pace of oncology drug discovery.
Polyclonal stable cell lines, also known as stable cell pools, are generated by transfecting host cells with a target gene or reporter gene construct, followed by antibiotic selection to enrich positively integrated cell populations. Unlike monoclonal cell lines derived from a single progenitor cell, polyclonal cell pools consist of a heterogeneous mixture of clones with varying integration sites and expression levels. Polyclonal cell lines offer several significant advantages for early-stage research. The timeline from transfection to generation is only 4–6 weeks, substantially shorter than the 9–15 weeks typically required for monoclonal development. The mixed-clone nature of polyclonal pools provides broader representation of expression profiles, allowing researchers to rapidly assess whether a construct is functionally active before committing to the more time-intensive monoclonal development process.
Polyclonal cell lines are important tools in the early drug discovery phase. Their rapid turnaround time and lower cost enable researchers to efficiently screen multiple candidate genes or constructs at the early stage, providing critical data to support subsequent studies and accelerating research decision-making. Consequently, polyclonal cell lines have become indispensable tools in early-stage oncology drug discovery and proof-of-concept studies.
Alfa Cytology provides professional polyclonal stable cell line construction services dedicated to transforming your gene research needs into ready-to-use cellular models in the fastest and most efficient manner. From vector design, gene delivery and stable selection, to cell pool expansion and quality validation, we offer customized solutions covering the entire workflow.
| Service Step | Service Details | Turnaround Time |
|---|---|---|
| Expression Vector Construction | Design and synthesize target gene expression vectors (with antibiotic selection markers or fluorescent markers) based on client requirements, and complete sequence verification.
|
2–3 weeks |
| Cell Transfection and Stable Pool Selection | Transfect expression vectors into host cells (CHO, HEK293, NIH/3T3, or client-specified cell lines) and enrich stably integrated cell populations through antibiotic selection.
|
3–4 weeks |
| Polyclonal Pool Expansion | Expand the selected stable transfection pools through culture and cryopreserve early-passage stocks to ensure traceability for subsequent experiments.
|
1 week |
| Expression Level Confirmation | Assess target gene expression at mRNA or protein levels and issue an expression validation report.
|
1–2 weeks |
| Quality Testing and Delivery | Complete quality testing and deliver cryopreserved cells with a comprehensive COA report.
|
1–2 weeks |
Our polyclonal stable cell line construction services support a broad spectrum of cancer types, providing rapid and cost-effective cell pools for early-stage target validation, proof-of-concept studies, and preliminary functional screening, including but not limited to:
Ready to accelerate your oncology research with our polyclonal stable cell line construction services? Whether you need rapid cell pools for preliminary functional screening, early-stage target validation, or proof-of-concept studies, Alfa Cytology provides fast, reliable, and cost-effective solutions tailored to your research needs. Please contact our scientific team today to discuss your project requirements and learn how our polyclonal stable cell line construction expertise can expedite your drug discovery programs.
For research use only.
Alfa Cytology, a preclinical research solution provider, provides its clients with one-stop solutions to accelerate cancer therapeutics discovery and development.
Copyright © 2026 Alfa Cytology. All rights reserved.
